Frequency Therapeutics to Discontinue FX-322 Hearing Loss …
WEBFeb 13, 2023 · Headquartered in Lexington, Mass., Frequency Therapeutics is pioneering a new category in regenerative medicine that aims to restore human function by developing therapeutics that activate a person’s innate regenerative potential within the body through the activation of progenitor cells.
Frequency Therapeutics Inc (FREQ) Announces Merger and …
WEBNov 6, 2023 · Frequency Therapeutics Inc (NASDAQ:FREQ) has completed its merger with Korro Bio, Inc. The company has also announced a private placement of $117 million.
Reversing hearing loss with regenerative therapy - MIT News
WEBMar 29, 2022 · The MIT spinout Frequency Therapeutics uses a new kind of druggable regenerative therapy that targets progenitor cells to create hair cells of the inner ear and reverse hearing loss.
Frequency Therapeutics Completes Enrollment of Phase 2b …
WEBOct 12, 2022 · Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore human function – first in hearing loss and then in multiple sclerosis – by developing therapeutics...
Astellas Pharma and Frequency Therapeutics collaborate on …
WEBAug 13, 2024 · Astellas Pharma recently announced that it had entered into an agreement with Frequency Therapeutics to co-develop and commercialise FX-322, a regenerative therapy to treat hearing loss.
Frequency Therapeutics Announces New FX-322 Results …
WEBSep 22, 2021 · FX-322 is designed to regenerate auditory sensory hair cells located in the cochlea within the inner ear and to potentially restore hearing in individuals with SNHL.
Biotech company aims to treat sudden hearing loss with early …
WEBDec 22, 2022 · While there isn't a drug on the market to restore hearing, a company called Frequency Therapeutics is testing a potential treatment for the condition commonly known as sudden deafness.
Frequency Therapeutics Releases New Data from Two FX-322 …
WEBMar 23, 2021 · WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). The interim results show that...
Frequency Therapeutics redesigns study after disappointing …
WEBNov 9, 2021 · Founded in 2015, Frequency Therapeutics has focused on a regenerative medicine approach to hearing loss. The approach is centered on revamping progenitor cells that eventually...
An Update on Frequency Therapeutics Clinical Trials of FX-322 …
WEBDec 27, 2022 · Nearly one year ago, Drs. Kevin Frank and Carl LeBel were on TWiH to discuss the exciting possibilities of regenerative medicine in hearing and the incredible progress, Frequency Therapeutics, has made on understanding the potential of applying it to clinical practice.